Core Points - Burning Rock Biotech Limited has regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price of $1.00 per share for 10 consecutive business days [1][3] - The company was previously notified on December 29, 2023, that it was not in compliance due to its American depositary shares (ADSs) closing below the minimum bid price for 30 consecutive business days [2] - To regain compliance, the company adjusted the ratio of its ADSs from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares, effective May 15, 2024 [2] Company Overview - Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, offering NGS-based therapy selection testing for late-stage cancer patients and cancer early detection services [4] - The company's mission is to guard life via science, and it has progressed its early detection services beyond proof-of-concept R&D into the clinical validation stage [4]

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in Chin ...

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic prod ...

Burning Rock Biotech Limited (NASDAQ:BNR) Q1 2023 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Yusheng Han - Founder and Chief Executive Officer Leo Li - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Burning Rock’s 2024 First Quarter Earnings Conference Call. At this time all participants are in listen-only mode. Please be advised that this conference is being recorded. Before we begin, I'd like to remind you tha ...

Financial Performance & Efficiency - Burning Rock's Q1 2024 revenues reached RMB 125.6 million, a 4% increase QoQ, but a 12% decrease YoY[33] - Non-GAAP gross profit for Q1 2024 was RMB 93.0 million, a 7% increase QoQ, but a 14% decrease YoY[33] - The company is driving sales efficiency, expecting selling expenses to be below 40% going forward[20] - Non-GAAP general and administrative expenses decreased from RMB 51 million in Q1 2023 to RMB 38 million in Q1 2024, a 26% decrease[30,31] - The company's commercial operation (excluding R&D expenses) reached profitability in Q1 2024[32] MRD & Early Detection Technology - Burning Rock's MRD assay, brPROPHET™, demonstrated a median lead time of 299 days to radiological recurrence in NSCLC[43] - In a study, brPROPHET™ detected preoperative ctDNA in 97% (113/117) of colorectal cancer patients[136,141] - For early cancer detection, the THUNDER study (N=2,385) completed with 98.9% specificity and 69.1% sensitivity, top-2 predicted origin accuracy of 91.7% (independent validation cohort)[67,79] - The PROMISE study demonstrated 83.7% sensitivity and 98.3% specificity for 9 cancers[103] Therapy Selection - Burning Rock's liquid biopsy product, Lung Plasma v4 (BRP2), demonstrated globally competitive performance in an analytical validation study[150,160]

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Con ...

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and th ...

GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) o ...

Group 1 - Burning Rock Biotech Limited plans to release its unaudited financial results for Q1 2024 on May 29, 2024, before the U.S. market opens [1] - A conference call will be held on the same day at 8:00 a.m. ET to discuss the financial results [1] - Participants must register in advance for the conference call and can access a live and archived webcast on the company's investor relations website [2] Group 2 - Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, offering NGS-based therapy selection testing and cancer early detection [3] - The company's early detection technology has progressed from proof-of-concept R&D to the clinical validation stage [3]

GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that, as previously announced on April 26, 2024, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A o ...